Opioid Agonist Therapy During Hospitalization Within the Veterans Health Administration: a Pragmatic Retrospective Cohort Analysis.


Journal

Journal of general internal medicine
ISSN: 1525-1497
Titre abrégé: J Gen Intern Med
Pays: United States
ID NLM: 8605834

Informations de publication

Date de publication:
08 2020
Historique:
received: 28 09 2019
accepted: 20 03 2020
pubmed: 16 4 2020
medline: 15 5 2021
entrez: 16 4 2020
Statut: ppublish

Résumé

Hospitalization of patients with opioid use disorder (OUD) is increasing, yet little is known about opioid agonist therapy (OAT: methadone and buprenorphine) administration during admission. Describe and examine patient- and hospital-level characteristics associated with OAT receipt during hospitalization in the Veterans Health Administration (VHA). A total of 12,407 unique patients, ≥ 18 years old, with an OUD-related ICD-10 diagnosis within 12 months prior to or during index hospitalization in fiscal year 2017 from 109 VHA hospitals in the continental U.S. OAT received during hospitalization. Few admissions received OAT (n = 1914; 15%) and when provided it was most often for withdrawal management (n = 834; 7%). Among patients not on OAT prior to admission who survived hospitalization (n = 10,969), 2.0% (n = 203) were newly initiated on OAT with linkage to care after hospital discharge. Hospitals varied in the frequency of OAT delivery (range, 0 to 43% of qualified admissions). Patients with pre-admission OAT (adjusted odds ratio [AOR] = 15.30; 95% CI [13.2, 17.7]), acute OUD diagnosis (AOR = 2.3; 95% CI [1.99, 2.66]), and male gender (AOR 1.52; 95% CI [1.16, 2.01]) had increased odds of OAT receipt. Patients who received non-OAT opioids (AOR 0.53; 95% CI [0.46, 0.61]) or surgical procedures (AOR 0.75; 95% CI [0.57, 0.99]) had decreased odds of OAT receipt. Large-sized (AOR = 2.0; 95% CI [1.39, 3.00]) and medium-sized (AOR = 1.9; 95% CI [1.33, 2.70]) hospitals were more likely to provide OAT. In a sample of VHA inpatient medical admissions, OAT delivery was infrequent, varied across the health system, and was associated with specific patient and hospital characteristics. Policy and educational interventions should promote hospital-based OAT delivery.

Sections du résumé

BACKGROUND
Hospitalization of patients with opioid use disorder (OUD) is increasing, yet little is known about opioid agonist therapy (OAT: methadone and buprenorphine) administration during admission.
OBJECTIVE
Describe and examine patient- and hospital-level characteristics associated with OAT receipt during hospitalization in the Veterans Health Administration (VHA).
PARTICIPANTS
A total of 12,407 unique patients, ≥ 18 years old, with an OUD-related ICD-10 diagnosis within 12 months prior to or during index hospitalization in fiscal year 2017 from 109 VHA hospitals in the continental U.S.
MAIN MEASURE
OAT received during hospitalization.
KEY RESULTS
Few admissions received OAT (n = 1914; 15%) and when provided it was most often for withdrawal management (n = 834; 7%). Among patients not on OAT prior to admission who survived hospitalization (n = 10,969), 2.0% (n = 203) were newly initiated on OAT with linkage to care after hospital discharge. Hospitals varied in the frequency of OAT delivery (range, 0 to 43% of qualified admissions). Patients with pre-admission OAT (adjusted odds ratio [AOR] = 15.30; 95% CI [13.2, 17.7]), acute OUD diagnosis (AOR = 2.3; 95% CI [1.99, 2.66]), and male gender (AOR 1.52; 95% CI [1.16, 2.01]) had increased odds of OAT receipt. Patients who received non-OAT opioids (AOR 0.53; 95% CI [0.46, 0.61]) or surgical procedures (AOR 0.75; 95% CI [0.57, 0.99]) had decreased odds of OAT receipt. Large-sized (AOR = 2.0; 95% CI [1.39, 3.00]) and medium-sized (AOR = 1.9; 95% CI [1.33, 2.70]) hospitals were more likely to provide OAT.
CONCLUSIONS
In a sample of VHA inpatient medical admissions, OAT delivery was infrequent, varied across the health system, and was associated with specific patient and hospital characteristics. Policy and educational interventions should promote hospital-based OAT delivery.

Identifiants

pubmed: 32291723
doi: 10.1007/s11606-020-05815-0
pii: 10.1007/s11606-020-05815-0
pmc: PMC7403377
doi:

Substances chimiques

Analgesics, Opioid 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

2365-2374

Subventions

Organisme : NIDA NIH HHS
ID : R33 DA035640
Pays : United States
Organisme : NIDA NIH HHS
ID : UG1 DA015815
Pays : United States
Organisme : HSRD VA
ID : IK2 HX001516
Pays : United States
Organisme : NIDA NIH HHS
ID : F30 DA044700
Pays : United States
Organisme : VA
ID : IK2HX001516
Pays : United States
Organisme : NIDA NIH HHS
ID : F30 DA044700UG
Pays : United States

Références

Subst Abus. 2019;40(3):285-291
pubmed: 30759050
Subst Abus. 2018;39(2):139-144
pubmed: 29595375
Subst Use Misuse. 2019;54(8):1376-1384
pubmed: 30945955
J Subst Abuse Treat. 2020 Mar;110:59-65
pubmed: 31952629
J Gen Intern Med. 2019 Dec;34(12):2796-2803
pubmed: 31410816
J Subst Abuse Treat. 2018 Dec;95:43-47
pubmed: 30352669
J Subst Abuse Treat. 2015 Nov;58:62-6
pubmed: 26251046
J Hosp Med. 2018 Apr 25;13(11):752-758
pubmed: 29694454
J Gen Intern Med. 2017 Mar;32(3):296-303
pubmed: 27957661
Drug Alcohol Depend. 2012 May 1;122(3):241-6
pubmed: 22115887
Psychiatr Serv. 2016 Nov 1;67(11):1262-1264
pubmed: 27247179
J Subst Abuse Treat. 2017 Aug;79:1-5
pubmed: 28673521
Am J Prev Med. 2019 Jun;56(6):875-881
pubmed: 31003811
Am J Med. 2016 May;129(5):481-5
pubmed: 26597670
Med Care. 2011 Apr;49(4):393-6
pubmed: 21407033
Health Aff (Millwood). 2016 May 1;35(5):832-7
pubmed: 27140989
J Hosp Med. 2019 Aug 16;14(10):633-635
pubmed: 31433765
J Addict Med. 2019 Mar/Apr;13(2):104-112
pubmed: 30608266
JAMA Intern Med. 2014 Aug;174(8):1369-76
pubmed: 25090173
J Hosp Med. 2017 May;12(5):339-342
pubmed: 28459904
J Hosp Med. 2019 Oct 23;14:E1-E4
pubmed: 31634100
Health Aff (Millwood). 2008 Jan-Feb;27(1):269-80
pubmed: 18180503
JAMA Psychiatry. 2019 Mar 1;76(3):229-230
pubmed: 30586140
J Addict Med. 2019 Jul/Aug;13(4):306-313
pubmed: 30633044
Am J Drug Alcohol Abuse. 2013 Mar;39(2):103-7
pubmed: 23421571

Auteurs

Kelsey C Priest (KC)

School of Medicine, MD/PhD Program, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Mail Code: L357, Portland, OR, 97239, USA. priest@ohsu.edu.
School of Public Health, Oregon Health & Science University-Portland State University, Portland, OR, USA. priest@ohsu.edu.

Travis I Lovejoy (TI)

School of Public Health, Oregon Health & Science University-Portland State University, Portland, OR, USA.
Department of Psychiatry, Oregon Health & Science University, Portland, OR, USA.
Center to Improve Veteran Involvement in Care, VA Portland Health Care System, Portland, OR, USA.

Honora Englander (H)

Division of Hospital Medicine & Section of Addiction Medicine, Department of Medicine, Oregon Health & Science University, Portland, OR, USA.

Sarah Shull (S)

Center to Improve Veteran Involvement in Care, VA Portland Health Care System, Portland, OR, USA.

Dennis McCarty (D)

School of Public Health, Oregon Health & Science University-Portland State University, Portland, OR, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH